A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MuSicalE
- Sponsors Roche
- 28 Jun 2022 Results of 1-year follow-up data assessing (n=1720) the real-world effectiveness and safety of ocrelizumab for treating patients with multiple sclerosis, presented at the 8th Congress of the European Academy of Neurology.
- 10 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2021 Status changed from active, no longer recruiting to recruiting.